Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine
Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.
In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.
| 2nd Annual Lyophilisation Conference |
|
|
|
|
2nd Annual Lyophilisation Conference
Boosting stability, delivery and longevity for pharmaceuticals and biotechnology
Background Info • Felix Franks, Director, BioUpdate Foundation
Although the commonest way to ensure longevity and stability for complex molecules, lyophilisation remains costly, complex and facility-intensive. Fine-tuning cycle parameters and trial-and-error experimentation also means the procedure remains as much of an art as a science. As reducing development time becomes increasingly important in today's economic climate, a rational, empirical approach to cycle design can save you time and money, especially when upscaling. More importantly, a robust lyophilisation cycle will guarantee a safe and effective product. Mastering these complex and inter-related requirements is no mean feat and Visiongain's 2nd Annual Lyophilisation conference provides distilled, market-focussed intelligence from development to production. With a workshop and sessions led by experts, you will gain a thorough understanding to provide the best outcome for your business, whether pharma or biotechnology. Case studies from industry will offer strategic insights to help you optimise key input and output parameters, and troubleshoot challenges from sterilisation and process optimisation, to dealing with temperature-sensitive molecules, viruses and cells. In addition you will also gain the latest insights into: Who will be there? |